Trial Profile

A Phase 1b, Open-label, Pilot Study of CLN-978 Administered Subcutaneously for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLN 978 (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions
Acronyms OUTRACE SLE

Most Recent Events

06 Aug 2026 According to Cullinan Therapeutics media release, in Q4 2026, the Company plans to share initial multi-dose regimen data. The Company also plans to begin Phase 2 expansion in early 2027 in patients with SLE and in patients with lupus nephritis.
10 Jun 2026 According to Cullinan Therapeutics media release, The company plans to report additional multi-dose regimen data for SLE in Q4 2026
10 Jun 2026 Results presented in the Cullinan Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com